APA

Forero-Torres A., Ramchandren R., Yacoub A., Wertheim M. S., Edenfield W. J., Caimi P., Gutierrez M., Akard L., Escobar C., Call J., Persky D., Iyer S., DeMarini D. J., Zhou L., Chen X., Dawkins F. & Phillips T. J. (20191223). Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. : Blood.

Chicago

Forero-Torres Andres, Ramchandren Radhakrishnan, Yacoub Abdulraheem, Wertheim Michael S, Edenfield William J, Caimi Paolo, Gutierrez Martin, Akard Luke, Escobar Carolina, Call Justin, Persky Daniel, Iyer Swaminathan, DeMarini Douglas J, Zhou Li, Chen Xuejun, Dawkins Fitzroy and Phillips Tycel J. 20191223. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. : Blood.

Harvard

Forero-Torres A., Ramchandren R., Yacoub A., Wertheim M. S., Edenfield W. J., Caimi P., Gutierrez M., Akard L., Escobar C., Call J., Persky D., Iyer S., DeMarini D. J., Zhou L., Chen X., Dawkins F. and Phillips T. J. (20191223). Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. : Blood.

MLA

Forero-Torres Andres, Ramchandren Radhakrishnan, Yacoub Abdulraheem, Wertheim Michael S, Edenfield William J, Caimi Paolo, Gutierrez Martin, Akard Luke, Escobar Carolina, Call Justin, Persky Daniel, Iyer Swaminathan, DeMarini Douglas J, Zhou Li, Chen Xuejun, Dawkins Fitzroy and Phillips Tycel J. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. : Blood. 20191223.